FDA Issues CRL for Oxylanthanum Carbonate in Hyperphosphatemia for CKD Patients on Dialysis
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Unicycive Therapeutics for oxylanthanum carbonate (OLC) in the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.1 The decision …